tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

PRLD Stock Latest News

Prelude Therapeutics Appoints Katina Dorton to Board
Company AnnouncementsPrelude Therapeutics Appoints Katina Dorton to Board
9d ago
8K
PRLD
Prelude Therapeutics appoints Katina Dorton to board of directors
PremiumThe Fly
Prelude Therapeutics appoints Katina Dorton to board of directors
9d ago
PRLD
Prelude Therapeutics: Promising SMARCA2-Targeted Degraders and Positive Outlook Support Buy Rating
PremiumRatings
Prelude Therapeutics: Promising SMARCA2-Targeted Degraders and Positive Outlook Support Buy Rating
1M ago
PRLD
Prelude Therapeutics Regains Nasdaq Compliance
PremiumCompany Announcements
Prelude Therapeutics Regains Nasdaq Compliance
1M ago
8K
PRLD
Prelude Therapeutics price target lowered to $3 from $4 at Citizens JMP
PremiumThe Fly
Prelude Therapeutics price target lowered to $3 from $4 at Citizens JMP
2M ago
PRLD
Prelude Therapeutics Reports Q2 2025 Financial Results
PremiumCompany AnnouncementsPrelude Therapeutics Reports Q2 2025 Financial Results
2M ago
PRLD
Prelude Therapeutics Pauses Intravenous SMARCA2 Degrader Development
Premium
Company Announcements
Prelude Therapeutics Pauses Intravenous SMARCA2 Degrader Development
2M ago
8K
PRLD
Prelude Therapeutics reports Q2 EPS (41c), consensus (43c)
Premium
The Fly
Prelude Therapeutics reports Q2 EPS (41c), consensus (43c)
2M ago
PRLD
PRLD Earnings Report this Week: Is It a Buy, Ahead of Earnings?
PremiumPre-Earnings
PRLD Earnings Report this Week: Is It a Buy, Ahead of Earnings?
3M ago
PRLD
Prelude Therapeutics Advances Cancer Treatment with PRT7732 Study
PremiumCompany Announcements
Prelude Therapeutics Advances Cancer Treatment with PRT7732 Study
3M ago
PRLD
Prelude Therapeutics’ PRT7732 Study: A Potential Game-Changer for SMARCA4 Mutations
PremiumCompany Announcements
Prelude Therapeutics’ PRT7732 Study: A Potential Game-Changer for SMARCA4 Mutations
4M ago
PRLD
Prelude Therapeutics Advances PRT3789 in Phase 1 Study for SMARCA4 Mutant Tumors
PremiumCompany Announcements
Prelude Therapeutics Advances PRT3789 in Phase 1 Study for SMARCA4 Mutant Tumors
4M ago
PRLD
Prelude Therapeutics Advances Cancer Treatment with New Phase 2 Study
PremiumCompany AnnouncementsPrelude Therapeutics Advances Cancer Treatment with New Phase 2 Study
4M ago
PRLD
Prelude Therapeutics Appoints Paul Scherer as Director
Premium
Company Announcements
Prelude Therapeutics Appoints Paul Scherer as Director
4M ago
8K
PRLD
Prelude Therapeutics Reports Q1 2025 Financial Results
Premium
Company Announcements
Prelude Therapeutics Reports Q1 2025 Financial Results
6M ago
PRLD
Prelude Therapeutics Reports Strong Q1 2025 Financial Results
PremiumCompany Announcements
Prelude Therapeutics Reports Strong Q1 2025 Financial Results
6M ago
8K
PRLD
Prelude Therapeutics’ PRT3789 Shows Promising Selectivity in SMARCA2 Degradation, Justifying Buy Rating
PremiumRatings
Prelude Therapeutics’ PRT3789 Shows Promising Selectivity in SMARCA2 Degradation, Justifying Buy Rating
6M ago
PRLD
Prelude Therapeutics: Solid Financial Position and Promising Clinical Catalysts Amidst Risks
PremiumRatings
Prelude Therapeutics: Solid Financial Position and Promising Clinical Catalysts Amidst Risks
7M ago
PRLD
Prelude Therapeutics CEO buys $467K in common stock
PremiumThe Fly
Prelude Therapeutics CEO buys $467K in common stock
7M ago
PRLD
Prelude Therapeutics Reports 2024 Financial Results
PremiumCompany AnnouncementsPrelude Therapeutics Reports 2024 Financial Results
8M ago
PRLD
Prelude Therapeutics Reports 2024 Financial Results and Updates
Premium
Company Announcements
Prelude Therapeutics Reports 2024 Financial Results and Updates
8M ago
8K
PRLD
Prelude Therapeutics reports FY24 EPS ($1.68), consensus ($1.77)
Premium
The Fly
Prelude Therapeutics reports FY24 EPS ($1.68), consensus ($1.77)
8M ago
PRLD

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >